A Pilot Study of Bone Mineral Density in Postmenopausal Women After Treatment for Breast Cancer

Inclusion Criteria:

Documented diagnosis of breast cancer
Last menstrual period occurring more than 5 years ago
Non-metastatic breast cancer tumor with the diagnosis of Tis, Tl-T4, N0-3, M0
DCIS is allowed, but LCIS (only) is not

Exclusion Criteria:

Any metabolic bone disease other than postmenopausal osteoporosis or osteopenia
Use of systemic gonadal hormonal medications or supplements within the past 24 months
Prior use of tamoxifen or raloxifene is permitted if the medication was discontinued more than 24 months prior to the diagnosis of breast cancer.
No adjuvant antiestrogen, antineoplastic, therapies are permitted on study.
Chronic use of systemic steroids for disease process other than breast cancer chemotherapy premedication or antiemetics
History of rheumatoid arthritis, ankylosing spondylitis, hyperparathyroidism, renal osteodystrophy, moderate to severe inflammatory or autoimmune disease or newly diagnosed thyroid condition requiring titration of medications.
Lobular carcinoma in situ or Stage IV breast cancer and patients with a concurrently active second malignancy other then adequately treated non-melanoma skin cancers or in situ cervical cancer.
participation in other clinical trials that are measuring BMD as a study parameter
Patients with conditions that are expected to distort BMD reading and make DEXA results unreliable
Patients with concurrent medical or psychiatric conditions that would keep them from understanding and complying with this clinical trial.